HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 3, 2009, Pages 316-322

  Stariat, Ján ^a   Kovaříková, Petra ^a   Klimeš, Jiří ^a   Lovejoy, David B ^b   Kalinowski, Danuta S ^b   Richardson, Des R ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

2 hydroxy 1 naphthylaldehyde 4 methyl 3 thiosemicarbazone (N4mT); Di 2 pyridylketone 4,4 dimethyl 3 thiosemicarbazone (Dp44mT); HPLC; Stability; Thiosemicarbazone

Indexed keywords

2-HYDROXY-1-NAPHTHYLALDEHYDE-4-METHYL-3-THIOSEMICARBAZONE (N4MT); ANTI-CANCER DRUGS; DI-2-PYRIDYLKETONE-4,4-DIMETHYL-3-THIOSEMICARBAZONE (DP44MT); HPLC; HPLC COLUMNS; HPLC METHODS; IN VITRO; PLASMA SAMPLES; THIOSEMICARBAZONE; THIOSEMICARBAZONES;

ACETONITRILE; AMINES; PHENOLS; PLASMAS; TUMORS;

PLASMA STABILITY;

ACETONITRILE; ANTINEOPLASTIC AGENT; DP44MT; EDETIC ACID; N4MT; THIOSEMICARBAZONE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DATA INTERPRETATION, STATISTICAL; DRUG STABILITY; HUMANS; ISONIAZID; NAPHTHALENES; PYRIDOXAL; RABBITS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SWINE; THIOSEMICARBAZONES;

EID: 58149186443     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.11.044     Document Type: Article

References (21)

1. Yu Y., Wong J., Lovejoy D.B., Kalinowski D.S., and Richardson D.R. Clin. Cancer Res. 23 (2006) 6876
2. Richardson D.R., Kalinowski D.S., Lau S., Jansson P.J., and Lovejoy D.B. Biochim. Biophys. Acta (2008) 10.1016/j.bbagen.2008.04.003
3. Buss J.L., Torti F.M., and Torti S.V. Curr. Med. Chem. 10 (2003) 1021
4. Kalinowski D.S., and Richardson D.R. Pharmacol. Rev. 57 (2005) 547
5. Richardson D., Ponka P., and Baker E. Cancer Res. 54 (1994) 685
6. Lovejoy D.B., and Richardson D.R. Blood 100 (2002) 666
7. Becker E., Lovejoy D.B., Greer J., Watts R., and Richardson D.R. Br. J. Pharmacol. 138 (2003) 819
8. Richardson D.R., Tran E.H., and Ponka P. Blood 86 (1995) 4295
9. Green D.A., Antholine W.E., Wong S.J., Richardson D.R., and Chitambar C.R. Clin. Cancer Res. 11 (2001) 3574
10. Yuan J., Lovejoy D.B., and Richardson D.R. Blood 104 (2004) 1450
11. Whitnall M., Howard J., Ponka P., and Richardson D.R. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 14901
12. Richardson R., Sharpe P.C., Lovejoy D.B., Senaratne D., Kalinowski D.S., Islam M., and Bernhardt P.V. J. Med. Chem. 49 (2006) 6510
13. Kalinowski D.S., and Richardson D.R. Chem. Res. Toxicol. 20 (2007) 715
14. Kovarikova P., Klimes J., Sterba M., Popelova O., Mokry M., Gersl V., and Ponka P. J. Sep. Sci. 28 (2005) 1300
15. Kovarikova P., Klimes J., Sterba M., Popelova O., Gersl V., and Ponka P. J. Chromatogr. B 838 (2006) 107
16. Kovaríková P., Mrkvicková Z., and Klimes J. J. Pharm. Biomed. Anal. 47 (2008) 360
17. Mrkvicková Z., Kovaríková P., Klimes J., Kalinowski D., and Richardson D.R. J. Pharm. Biomed. Anal. 43 (2007) 1343
18. Feun L., Modiano M., Lee K., Mao J., Marini A., Savaraj N., Plezia P., Almassian B., Colacino E., Fischer J., and MacDonald S. Cancer Chemother. Pharmacol. 50 (2002) 223
19. Murren J., Modiano M., Clairmont C., Lambert P., Savaraj N., Doyle T., and Sznol M. Clin. Cancer Res. 11 (2003) 409
20. CDER and CVM. Bioanalytical Method Validation, Guidance for Industry, May 2001, http://www.fda.gov/cder/guidance/4252fnl.htm).
21. Kalinowski D.S., Yu Y., Sharpe P.S., Islam M., Liao Y.-T., Lovejoy D.B., Kumar N., Bernhardt P.V., and Richardson D.R. J. Med. Chem. 50 (2007) 3716